ViRAZE is an emerging biotechnology company utilizing a patented high throughput screening (HTS) technology to discover and develop new small molecules to treat viral diseases. Our initial emphasis is on viral dermatology diseases that have unsatisfactory treatment options. We are seeking funding for the operation to develop our lead program (VIR001) to be the first approved treatment for Molluscum contagiosum and partners interested in co-development for other diseases.